HemaSphere (Jun 2022)

P926: DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE FOR TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND SEVERE RENAL IMPAIRMENT: RESULTS FROM THE PHASE 2 GMMG-DANTE TRIAL

  • L. Leypoldt,
  • M. Gavriatopoulou,
  • B. Besemer,
  • H. Salwender,
  • M.-S. Raab,
  • A. Nogai,
  • C. Khandanpour,
  • V. Runde,
  • M. Zago,
  • P. Martus,
  • H. Goldschmidt,
  • C. Bokemeyer,
  • M. Dimopoulos,
  • K. Weisel

DOI
https://doi.org/10.1097/01.HS9.0000846572.66058.38
Journal volume & issue
Vol. 6
pp. 816 – 817

Abstract

Read online

No abstracts available.